We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SPX:SPREADEXSPX 500, Daily Analysis

Data as of 2026-06-14 - not real-time

$230.05

Latest Price

8/10Risk

Risk Level: High

Executive Summary

SPX Technologies is trading at $230.05, comfortably above its 20‑day SMA of $218.75 and 50‑day SMA of $214.63, with a bullish MACD histogram (+$1.03) and rising volume, indicating short‑term momentum strength. RSI sits at 58.5, suggesting room for upside without immediate overbought pressure, while the price remains well within the technical range bounded by a support of $191.24 and resistance near $244.64.
Fundamentally, the company posted a 17.4% YoY revenue growth and maintains healthy operating (16.6%) and profit margins (10.8%). Forward earnings are projected at $9.06, cutting the forward P/E to 25.4 versus a trailing P/E of 44.1, and analysts (12) rate it a strong buy with a median target of $267.5, implying about a 15% upside. However, the current valuation appears stretched relative to peers (industry PE ~30.6) and a DCF fair value of $86.79, highlighting potential overvaluation.
Risk factors include elevated 30‑day volatility (42%) and a beta above 1.3, reflecting sensitivity to market swings, combined with a high debt‑to‑equity ratio (~29.5) and no dividend payout. The industrial building‑products sector adds cyclical exposure, while geographic diversification across North America, Europe, and China introduces moderate regulatory and currency considerations.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above 20‑day and 50‑day SMAs
  • Bullish MACD and increasing volume
  • High current P/E relative to industry

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 17% revenue growth and expanding margins
  • Forward P/E of 25 indicating earnings acceleration
  • Analyst consensus strong‑buy with ~15% target upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Robust cash flow generation versus elevated debt levels
  • Cyclical exposure in industrial sector
  • Absence of dividend and high valuation metrics

Key Metrics & Analysis

Financial Health

Revenue Growth17.40%
Profit Margin10.76%
P/E Ratio44.1
ROE13.85%
ROA6.53%
Debt/Equity29.49
P/B Ratio5.0
Op. Cash Flow$374.8M
Free Cash Flow$179.2M
Industry P/E30.6

Technical Analysis

TrendBullish
RSI58.5
Support$191.24
Resistance$244.64
MA 20$218.75
MA 50$214.63
MA 200$207.92
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value$86.79
Target Price$266.25
Upside/Downside15.74%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.36
Volatility42.26%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.